Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary Sjögren's syndrome~* ESSDAI score ≥ 6~Exclusion Criteria:~* Secondary Sjögren's syndrome~* Receiving cyclosphosphamide, corticosteroid bolus with dose over 1 mg/kg, rituximab, belimunab, other immunosuppressives.~* At significant risk for thromboembolic event~* Clinically significant systemic infection~* Significant elevated risk for infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CFZ533 active- Cohort 2 (Type: EXPERIMENTAL): multiple doses of CFZ533 intravenous infusion
- CFZ533 placebo- Cohort 2 (Type: PLACEBO_COMPARATOR): multiple doses of placebo intravenous infusion
- CFZ533 active - Cohort 1 (Type: EXPERIMENTAL): multiple doses of CFZ533 s.c. injection
- CFZ533 placebo - Cohort 1 (Type: PLACEBO_COMPARATOR): multiple doses of placebo s.c. injection
- CFZ533 Treatment Arm 1 - Cohort 3 (Type: EXPERIMENTAL): multiple doses of CFZ533 s.c. injection
- CFZ533 Treatment Arm 2 - Cohort 3 (Type: EXPERIMENTAL): Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection

Based on this trial design, predict the completion outcome and termination type (if applicable).